"Drug"

According to data from an ongoing Phase I/Ib clinical trial (NCT04374877), an innovative IL-27 inhibitor called SRF388 has shown promising results in the treatment of locally advanced or advanced non-small cell lung cancer (NSCLC), which undoubtedly brings new hope for the treatment of lung cancer patients in general!

A new clinical trial update shows that oxitinib (known as Teresa, or 9291) nearly doubled disease-free survival and halved post-operative recurrence rates in lung cancer patients carrying an early stage EGFR mutation!

The results of a new study recently showed that Olutasidenib monotherapy in patients with relapsed/refractory acute myeloid leukaemia carrying the IDH1 mutation elicited high rates of complete remission with manageable toxicity.

Data from a study recently published by the Royal Marsden Cancer Centre showed promising data for the combination of Avutometinib + Defactinib in the treatment of ovarian cancer, resulting in significant tumour shrinkage in 28% of patients and disease control in 93% of patients.

With more and more new cutting-edge drugs emerging, the standard treatment paradigm for breast cancer is now rapidly changing, and the future is looking brighter for patients.

The impact of AlphaFold on protein structure prediction has been transformative.

The US FDA has accelerated the approval of the new drug Pirtobrutinib for the treatment of relapsed or refractory set of cell lymphomas. The drug led to substantial tumour disappearance in 50% of patients, with 13% of them having complete tumour disappearance.

The results of a new study show that Ubamatamab, a bispecific antibody drug, has shown excellent results and a good safety profile in patients with ovarian cancer.

The FDA has recently granted orphan drug designation to Ezurpimtrostat, a PPT-1 inhibitor for the treatment of patients with hepatocellular carcinoma (HCC).

Nectin-4 is an important target that has been shown to be available as a treatment for locally advanced and advanced bladder cancer. Based on this, Padcev (enfortumab-vedotin-ejfv), the first ADC drug (antibody-coupled drug) for uroepithelial carcinoma, has also received accelerated FDA approval for the treatment of locally advanced or advanced bladder cancer in patients who have previously received immune checkpoint inhibitors (PD-L1, PD-1) and platinum-containing chemotherapy before surgery (neoadjuvant therapy) or after surgery (adjuvant therapy). Adult patients with advanced or late-stage uroepithelial carcinoma (a common type of bladder cancer).